NCT03222076View on ClinicalTrials.gov

Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 28, 2017

Primary Completion Date

September 14, 2022

Study Completion Date

September 14, 2022

Conditions
Hepatocellular CarcinomaResectable Hepatocellular Carcinoma
Interventions
BIOLOGICAL

Ipilimumab

Given IV

BIOLOGICAL

Nivolumab

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT03222076 - Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer | Biotech Hunter | Biotech Hunter